The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis.

Abstract

BACKGROUND AND AIMS:

Prader-Willi Syndrome (PWS) is a rare genetic disease. Oxytocin is a neuropeptide hormone that impacts fear, and social recognition. Intranasal administration of oxytocin can be utilized to treat PWS patients. The results of published trials assessing the effects of intranasal oxytocin in PWS are variable. The current systematic review aims to investigate the efficacy of oxytocin in Prader-Willi patients.

METHODS:

We conducted a systematic literature search on Pubmed, Web of Science, and Scopus from inception to March 2022 for relevant interventional randomized controlled trials (RCTs) reporting the effect of oxytocin in patients with Prader-Willi syndrome. We assessed the quality of included trials using the Cochrane tool risk of bias 1. We performed the meta-analysis with Revman software version 5.4. In addition, we visualized our results using forest plots. We assessed the heterogeneity by using the Chi-square test.

RESULTS:

Relevant to hyperphagia, the data extracted in three studies comprising 92 patients did not show positive outcomes of oxytocin compared to placebo (MD = 0.18; 95% CI: -0.44, 0.80; P = 0.56). Three studies that included 94 patients revealed no significant effects regarding weight between oxytocin and placebo (MD = 0.30; 95% CI: -0.22, 0.83; P = 0.25). The Aberrant Behaviour Checklist found that group-administered oxytocin improved behaviour compared to their counterpart who received a placebo.

CONCLUSION:

Oxytocin didn't have significant effects on hyperphagia or weight. To establish the impact of oxytocin in Prader-Willi patients, additional prospective, large-sample randomized controlled trials (RCTs) are needed to avoid controversy.

• Authors: Noran M Shalma, Mostafa A Alsharabasy, Amira M Taha, Ashraf Alsawareah, Emery Manirambona, Sirwan K Ahmed, Mohamed R Mohamed, Nouran A Taha, Mohamed Abd-ElGawad
• Journal: Diabetes & metabolic syndrome (Diabetes Metab Syndr) Vol. 17 Issue 2 Pg. 102711 (Feb 2023) ISSN: 1878-0334 [Electronic] Netherlands
• PMID: 36774885 (Publication Type: Meta-Analysis, Systematic Review, Journal Article, Review)
• Copyright: Copyright © 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.

Chemical References

• Oxytocin

Topics

• Humans
• Oxytocin (therapeutic use)
• Prader-Willi Syndrome (drug therapy)
• Administration, Intranasal
• Hyperphagia